Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Filed by CROSSROADS STRATEGIES, LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 19, 2025
Income
$50,000.00
Expenses
Not reported
Filing UUID
9a555ae2-bd95-4581-b54a-7293345ecc8b
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1492/S.832, EPIC Act of 2025.

Literal federal measure citations: H.R.1492, S.832

BUD · Budget/Appropriations

H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions.

Literal federal measure citations: H.R.1

CPT · Copyright/Patent/Trademark

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

TRD · Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

HCR · Health Issues

340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance; insulin price cap; PBM reform; TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.

Literal federal measure citations: S.2296, H.R.3838, S.891, S.527, S.1040, S.1041, S.1097, S.1095, S.1096

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.